Mesoblast is aiming to get 2012 approval for bone marrow treatment

05/12/2010 | Bloomberg Businessweek

Mesoblast, an Australian company that develops stem cell treatments, has agreed to acquire the remaining shares of Angioblast Systems that it doesn't yet own. The acquisition will give Mesoblast exclusive rights to various treatments, including a stem cell treatment that expands umbilical cord blood used in bone marrow transplants among leukemia patients. Mesoblast hopes to get the treatment approved by 2012.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI